US5316759A
(en)
*
|
1986-03-17 |
1994-05-31 |
Robert J. Schaap |
Agonist-antagonist combination to reduce the use of nicotine and other drugs
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5472943A
(en)
*
|
1992-09-21 |
1995-12-05 |
Albert Einstein College Of Medicine Of Yeshiva University, |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
|
US5512578A
(en)
*
|
1992-09-21 |
1996-04-30 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
|
USRE36547E
(en)
*
|
1992-09-21 |
2000-02-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
|
US5580876A
(en)
*
|
1992-09-21 |
1996-12-03 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US6096756A
(en)
*
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
CA2115792C
(en)
*
|
1993-03-05 |
2005-11-01 |
David J. Mayer |
Method for the treatment of pain
|
IL119660A
(en)
*
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
EP0661283B1
(de)
*
|
1993-07-19 |
1998-10-21 |
Toray Industries, Inc. |
Wirkstoff zum schutze von gehirnzellen
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
DE69631525T2
(de)
*
|
1995-03-03 |
2004-12-16 |
Endo Pharmaceuticals Inc. |
Verwendung von dextromethorphan oder dextrorphan zur behandlung der harninkontinenz
|
US5696115A
(en)
*
|
1995-04-21 |
1997-12-09 |
Eli Lilly And Company |
Method for treating nicotine withdrawal
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US5840731A
(en)
*
|
1995-08-02 |
1998-11-24 |
Virginia Commonwealth University |
Pain-alleviating drug composition and method for alleviating pain
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US6083920A
(en)
*
|
1995-12-21 |
2000-07-04 |
Ayurcore, Inc. |
Compositions for modulating intracellular inositol trisphosphate concentration
|
US20030125536A1
(en)
*
|
1996-01-11 |
2003-07-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
EP0906104A4
(de)
*
|
1996-03-25 |
2003-12-10 |
Lilly Co Eli |
Schmerzbehandlungsverfahren
|
AU5813098A
(en)
*
|
1997-01-09 |
1998-08-03 |
G.D. Searle & Co. |
Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain
|
ATE357226T1
(de)
*
|
1997-01-22 |
2007-04-15 |
Cornell Res Foundation Inc |
(d)-methadon, ein nicht-opioides schmerzmittel
|
US6962930B1
(en)
|
1997-06-06 |
2005-11-08 |
Lohocla Research Corporation |
Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage
|
AU8668598A
(en)
|
1997-08-20 |
1999-03-08 |
University Of Oklahoma, The |
Gaba analogs to prevent and treat gastrointestinal damage
|
US6306432B1
(en)
|
1997-09-08 |
2001-10-23 |
Chiron Corporation |
High and low load formulations of IGF-I in multivesicular liposomes
|
BR9812162A
(pt)
|
1997-09-08 |
2000-07-18 |
Warner Lambert Co |
Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
|
US6106858A
(en)
*
|
1997-09-08 |
2000-08-22 |
Skyepharma, Inc. |
Modulation of drug loading in multivescular liposomes
|
NZ503513A
(en)
*
|
1997-09-18 |
2004-12-24 |
Skyepharma Inc |
Sustained-release liposomal anesthetic compositions
|
US20020039596A1
(en)
|
1997-11-14 |
2002-04-04 |
Hartoun Hartounian |
Production of multivesicular liposomes
|
RU2241458C2
(ru)
|
1997-12-22 |
2004-12-10 |
Эро-Селтик, С.А. |
Комбинации агонист/антагонист опиоида
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
CN1204890C
(zh)
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
US20070197651A1
(en)
*
|
1998-03-09 |
2007-08-23 |
Tufts University |
Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
|
AU2981099A
(en)
|
1998-03-09 |
1999-09-27 |
Trustees Of Tufts College |
Treatment of compulsive behaviours in man and animals
|
US20060167114A1
(en)
*
|
1998-03-09 |
2006-07-27 |
Louis Shuster |
Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
|
US6007841A
(en)
*
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US6109269A
(en)
*
|
1999-04-30 |
2000-08-29 |
Medtronic, Inc. |
Method of treating addiction by brain infusion
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
EP2295043A1
(de)
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Hydrocodon-Formulierungen mit gesteuerter Freisetzung
|
WO2001040269A2
(en)
*
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
US6207674B1
(en)
*
|
1999-12-22 |
2001-03-27 |
Richard A. Smith |
Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
|
EP1935421A1
(de)
|
2000-02-08 |
2008-06-25 |
Euro-Celtique S.A. |
Kontrolliert freigesetzte Zusammensetzungen mit einem Opioid-Agonisten und einem Opioid-Antagonisten
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
JP2003522144A
(ja)
|
2000-02-08 |
2003-07-22 |
ユーロ−セルティーク,エス.エイ. |
オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
|
US6730691B1
(en)
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
KR20030060771A
(ko)
|
2000-04-28 |
2003-07-16 |
메모리얼 슬로안-케터링 캔서 센터 |
국소용 마취제/아편양약물 제제 및 이들의 용도
|
US20040024004A1
(en)
*
|
2001-05-04 |
2004-02-05 |
Sherman Barry M. |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
|
DE10025946A1
(de)
*
|
2000-05-26 |
2001-11-29 |
Gruenenthal Gmbh |
Wirkstoffkombination
|
CN101317825A
(zh)
|
2000-10-30 |
2008-12-10 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
US6780871B2
(en)
*
|
2001-01-29 |
2004-08-24 |
Albany Medical College |
Methods and compositions for treating addiction disorders
|
AU2002250256B2
(en)
*
|
2001-03-08 |
2008-04-03 |
Emory University |
pH-dependent NMDA receptor antagonists
|
US7820688B2
(en)
|
2001-04-27 |
2010-10-26 |
Memorial Sloan-Kettering Cancer Center |
Topical anesthetic/opioid formulations and uses thereof
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
CN1273075C
(zh)
*
|
2001-07-13 |
2006-09-06 |
爱科来株式会社 |
分析用具、具备分析用具的浓度测定装置用的穿刺元件一体化安装体及体液采取用具
|
SI1416842T1
(sl)
*
|
2001-07-18 |
2009-06-30 |
Euro Celtique Sa |
Farmacevtske kombinacije oksikodona in naloksona
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
ES2326794T3
(es)
|
2001-08-06 |
2009-10-20 |
Euro-Celtique S.A. |
Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20060173064A1
(en)
*
|
2001-08-24 |
2006-08-03 |
Lippa Arnold S |
(-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
|
US6569887B2
(en)
*
|
2001-08-24 |
2003-05-27 |
Dov Pharmaceuticals Inc. |
(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
|
WO2003061594A2
(en)
*
|
2002-01-23 |
2003-07-31 |
The Regents Of The University Of California |
Methods and compositions for reducing the development of drug tolerance and/or physical dependence
|
DE60332316D1
(de)
|
2002-02-01 |
2010-06-10 |
Euro Celtique Sa |
2-piperazinpyridine für die schmerzbehandlung
|
EP1480639A1
(de)
*
|
2002-02-22 |
2004-12-01 |
Warner-Lambert Company LLC |
Kombinationen eines alpha-2-delta-liganden mit einem selektiven cyclooxygenase-2-hemmer
|
US6974818B2
(en)
*
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
ES2546010T3
(es)
|
2002-04-05 |
2015-09-17 |
Euro-Celtique S.A. |
Preparación farmacéutica que contiene oxicodona y naloxona
|
US20030199439A1
(en)
*
|
2002-04-22 |
2003-10-23 |
Simon David Lew |
Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
|
US20030199496A1
(en)
*
|
2002-04-22 |
2003-10-23 |
Simon David Lew |
Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
|
US6864261B2
(en)
*
|
2002-05-02 |
2005-03-08 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
CA2486075A1
(en)
*
|
2002-05-13 |
2003-11-20 |
Endo Pharmaceuticals Inc. |
Abuse-resistant opioid solid dosage form
|
WO2004041154A2
(en)
*
|
2002-05-13 |
2004-05-21 |
Endo Pharmaceuticals Inc. |
Abuse-resistant opioid dosage form
|
MXPA04012748A
(es)
*
|
2002-06-28 |
2005-08-15 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor.
|
TWI326214B
(en)
*
|
2002-07-17 |
2010-06-21 |
Avanir Pharmaceuticals Inc |
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
US7262194B2
(en)
*
|
2002-07-26 |
2007-08-28 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US20080081834A1
(en)
|
2002-07-31 |
2008-04-03 |
Lippa Arnold S |
Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
PT1551372T
(pt)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
US20040127501A1
(en)
*
|
2002-09-24 |
2004-07-01 |
Zhengming Chen |
Therapeutic agents useful for treating pain
|
US7157462B2
(en)
*
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US7273889B2
(en)
*
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
US20070298999A1
(en)
*
|
2003-02-10 |
2007-12-27 |
Zaijie Wang |
Method for treating pain with a calmodulin inhibitor
|
US7256200B2
(en)
*
|
2003-02-10 |
2007-08-14 |
The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois |
Method and composition for potentiating an oplate analgesic
|
US20100113563A1
(en)
*
|
2004-01-30 |
2010-05-06 |
Zaijie Wang |
Method for Treating Pain with a Calmodulin Inhibitor
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
EP1613324A2
(de)
*
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Verfahren zur behandlung von schmerzen mit opioid-antagonisten
|
MY135852A
(en)
*
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US20040213828A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Smith David J. |
Pain relief lollipop compositions and methods
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
PL1641775T3
(pl)
*
|
2003-07-03 |
2009-07-31 |
Euro Celtique Sa |
Pochodne 2-pirydynoalkin użyteczne do leczenia bólu
|
EP1867644B1
(de)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
|
WO2005009987A1
(en)
*
|
2003-07-24 |
2005-02-03 |
Euro-Celtique S.A. |
Piperidine compounds and pharmaceutical compositions containing them
|
ATE431822T1
(de)
|
2003-07-24 |
2009-06-15 |
Euro Celtique Sa |
Zur behandlung oder vorbeugung von schmerzen geeignete heteroaryl-tetrahydropiperidyl- verbindungen
|
SI1648880T1
(sl)
|
2003-08-01 |
2010-05-31 |
Euro Celtique Sa |
Terapevtska sredstva uporabna za zdravljenje bolečine
|
PT1664016E
(pt)
*
|
2003-09-22 |
2008-12-29 |
Euro Celtique Sa |
Agentes terapêuticos úteis para tratamento da dor
|
PL2017276T3
(pl)
*
|
2003-09-22 |
2011-06-30 |
Euro Celtique Sa |
Związki fenylowo-karboksamidowe przydatne do leczenia bólu
|
SI1663229T1
(sl)
|
2003-09-25 |
2010-08-31 |
Euro Celtique Sa |
Farmacevtske kombinacije hidrokodona in naltreksona
|
US20060009478A1
(en)
*
|
2003-10-15 |
2006-01-12 |
Nadav Friedmann |
Methods for the treatment of back pain
|
DE602004019576D1
(de)
*
|
2003-12-30 |
2009-04-02 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete piperazine
|
US7404970B2
(en)
*
|
2004-04-13 |
2008-07-29 |
Konec, Inc. |
Pain relief composition, method to form same, and method to use same
|
US20050251442A1
(en)
*
|
2004-05-07 |
2005-11-10 |
Joseph Ficalora |
Consumer incentive system and business method
|
CN1968697B
(zh)
*
|
2004-05-14 |
2012-05-16 |
株式会社绿十字 |
右旋吗啡喃的神经保护特性
|
EP1604666A1
(de)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
HUE037643T2
(hu)
|
2004-06-12 |
2018-09-28 |
Collegium Pharmaceutical Inc |
Visszaélésre nem alkalmas gyógyszerkészítmények
|
US20070043100A1
(en)
|
2005-08-16 |
2007-02-22 |
Hagen Eric J |
Novel polymorphs of azabicyclohexane
|
US20060100263A1
(en)
*
|
2004-11-05 |
2006-05-11 |
Anthony Basile |
Antipyretic compositions and methods
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
US20060111307A1
(en)
*
|
2004-11-16 |
2006-05-25 |
Wendye Robbins |
Methods and compositions for treating pain
|
EP1702558A1
(de)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
US20060223786A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Smith David J |
Transdermal pain control method and device
|
WO2007016155A2
(en)
|
2005-07-27 |
2007-02-08 |
Dov Pharmaceutical, Inc. |
Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
|
US7968604B2
(en)
*
|
2005-09-23 |
2011-06-28 |
Jeong-Woo Cho |
Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate
|
JP2009525343A
(ja)
*
|
2006-02-03 |
2009-07-09 |
アバニール・ファーマシューティカルズ |
鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
|
US20070248657A1
(en)
*
|
2006-04-25 |
2007-10-25 |
Smith David J |
Multi-compartment transdermal pain control device
|
US20080045725A1
(en)
*
|
2006-04-28 |
2008-02-21 |
Murry Jerry A |
Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
PL2526932T3
(pl)
|
2006-06-19 |
2017-12-29 |
Alpharma Pharmaceuticals Llc |
Kompozycja farmaceutyczna
|
WO2008011596A2
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
EP1897543A1
(de)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine-Waffel zur Substitutionstherapie
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
BRPI0719260A2
(pt)
*
|
2006-10-09 |
2014-04-29 |
Smithkline Beecham Corp |
Composições para a redução de sintomas de supressão de nicotina e/ou do uso de tabaco.
|
US20080269348A1
(en)
*
|
2006-11-07 |
2008-10-30 |
Phil Skolnick |
Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
|
US8138377B2
(en)
*
|
2006-11-07 |
2012-03-20 |
Dov Pharmaceutical, Inc. |
Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
|
US20100048605A1
(en)
*
|
2006-12-11 |
2010-02-25 |
University Of Kentucky Research Foundation |
Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
|
EP2091936B1
(de)
*
|
2007-04-27 |
2013-05-15 |
Purdue Pharma LP |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
WO2008153937A2
(en)
*
|
2007-06-06 |
2008-12-18 |
Dov Pharmaceutical, Inc. |
Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
|
US9133159B2
(en)
|
2007-06-06 |
2015-09-15 |
Neurovance, Inc. |
1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
|
SG182964A1
(en)
|
2007-06-29 |
2012-08-30 |
Univ Emory |
Nmda receptor antagonists for neuroprotection
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100221313A1
(en)
*
|
2008-12-01 |
2010-09-02 |
Innovative Pharmaceuticals, Llc |
Transdermal reservoir patch
|
SG174286A1
(en)
|
2009-03-10 |
2011-10-28 |
Euro Celtique Sa |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US20110218213A1
(en)
*
|
2010-03-02 |
2011-09-08 |
Royster Jr George E |
Methods and Compositions for Treating or Preventing Symptoms of Hormonal Variations
|
MX2012012991A
(es)
|
2010-05-11 |
2012-11-30 |
Cima Labs Inc |
Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
|
ES2643291T3
(es)
|
2010-12-22 |
2017-11-22 |
Purdue Pharma L.P. |
Formas de dosificación de liberación controlada con cierre inviolable recubiertas
|
CA2822769C
(en)
|
2010-12-23 |
2016-10-04 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
US20130178618A1
(en)
|
2012-01-10 |
2013-07-11 |
William Allen Boulanger |
Novel pharmaceutical intermediates and methods for preparing the same
|
KR101840526B1
(ko)
|
2013-02-05 |
2018-03-20 |
퍼듀 퍼머 엘피 |
내변조성 제약 제제
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
PL3261721T3
(pl)
|
2015-02-25 |
2022-12-27 |
Prilenia Neurotherapeutics Ltd. |
Stososowanie pridopidyny w celu poprawy pamięci
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
EP3997092A4
(de)
|
2019-07-08 |
2023-09-06 |
University of Health Sciences & Pharmacy in St. Louis |
G-protein-beeinflusster opioidrezeptoragonist/analgetika mit reduzierter arrestinrekrutierung
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|